SMOLDERING PLASMA CELL MYELOMA

This study tests whether adding daratumumab to standard lenalidomide and dexamethasone can delay or prevent smoldering myeloma from turning into active multiple myeloma. About 288 people with high-risk smoldering myeloma will participate. The goal is to see if the combination imp…

This study tests a drug called iberdomide, alone or with dexamethasone, in people with smoldering multiple myeloma at intermediate or high risk of developing active cancer. The goal is to see if the treatment can shrink or control the cancer cells and delay progression to symptom…

This study looks at whether non-chemo approaches like physical activity, intermittent fasting, or adding a beta-blocker (propranolol) can improve immune function and quality of life in people with multiple myeloma or related blood disorders. About 175 adults with smoldering or ac…

This study looks at how people with early blood conditions (MGUS or smoldering myeloma) feel day-to-day. About 400 adults will fill out short questionnaires about their symptoms and concerns. The goal is to help doctors better understand what matters most to patients.

This study follows 200 people with early blood conditions (MGUS or smoldering myeloma) that sometimes turn into multiple myeloma, a blood cancer. Researchers will track age, protein levels, bone marrow cells, genes, and bone health to find clues that predict progression. No treat…